Brainstorm Cell TherapeuticsBCLI
About: Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
Employees: 29
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
85% more capital invested
Capital invested by funds: $2.22M [Q1] → $4.09M (+$1.87M) [Q2]
67% more call options, than puts
Call options by funds: $72K | Put options by funds: $43K
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
9.12% more ownership
Funds ownership: 8.33% [Q1] → 17.46% (+9.12%) [Q2]
2% more funds holding
Funds holding: 47 [Q1] → 48 (+1) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for BCLI.
